La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Arcoma Gestione

Gestione criteri di controllo 1/4

We currently do not have sufficient information about the CEO.

Informazioni chiave

Mattias Leire

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	1.5yrs
Proprietà del CEO	n/a
Durata media del management	1.3yrs
Durata media del Consiglio di amministrazione	7.6yrs

Aggiornamenti recenti sulla gestione

Have Insiders Sold Arcoma AB (STO:ARCOMA) Shares Recently?

Jan 14

Recent updates

At kr15.20, Is Arcoma AB (STO:ARCOMA) Worth Looking At Closely?

Aug 07

Is Now The Time To Look At Buying Arcoma AB (STO:ARCOMA)?

Apr 26

Arcoma AB's (STO:ARCOMA) P/E Is Still On The Mark Following 25% Share Price Bounce

Feb 06

Arcoma AB's (STO:ARCOMA) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Jan 12

These 4 Measures Indicate That Arcoma (STO:ARCOMA) Is Using Debt Reasonably Well

Dec 17

Estimating The Fair Value Of Arcoma AB (STO:ARCOMA)

Nov 21

AMMINISTRATORE DELEGATO

Mattias Leire (43 yo)

1.5yrs

Mandato

Mr. Mattias Leire is Chief Executive Officer of Arcoma AB from February 2023. He joined the Arcoma AB in 2023. He has extensive experience from leading positions, including many years within Atos Medical....

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Mattias Leire	Chief Executive Officer	1.5yrs	Nessun dato	Nessun dato
Johan Dahlberg	Chief Financial Officer	2.3yrs	Nessun dato	Nessun dato
Jesper Lindroos	Chief Operating Officer	1.1yrs	Nessun dato	Nessun dato
Tarik Cengiz	Global Sales Director	1.1yrs	Nessun dato	Nessun dato

1.3yrs

Durata media

40yo

Età media

Gestione esperta: ARCOMA's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Jan Wahlstrom	Independent Director	2.3yrs	SEK 100.00k	Nessun dato
Mats Thoren	Director	14.6yrs	SEK 100.00k	Nessun dato
Lars Kvarnhem	Chairman	7.6yrs	SEK 400.00k	Nessun dato

7.6yrs

Durata media

53yo

Età media

Consiglio di amministrazione esperto: ARCOMA's board of directors are considered experienced (7.6 years average tenure).

Arcoma Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Less than half of directors are independent

No independent directors

Director recently bought kr119k worth of stock

Arcoma AB, Annual General Meeting, May 25, 2021

Have Insiders Sold Arcoma AB (STO:ARCOMA) Shares Recently?

Insider recently sold kr390k worth of stock

Recent updates

Second quarter 2024 earnings released: EPS: kr0.28 (vs kr0.031 in 2Q 2023)

At kr15.20, Is Arcoma AB (STO:ARCOMA) Worth Looking At Closely?

First quarter 2024 earnings released: EPS: kr0.34 (vs kr0.18 loss in 1Q 2023)

Is Now The Time To Look At Buying Arcoma AB (STO:ARCOMA)?

Arcoma AB to Report Q1, 2024 Results on Apr 25, 2024

Investor sentiment improves as stock rises 17%

Arcoma AB's (STO:ARCOMA) P/E Is Still On The Mark Following 25% Share Price Bounce

Full year 2023 earnings: EPS in line with analyst expectations despite revenue beat

New major risk - Market cap size

Is Arcoma (STO:ARCOMA) A Risky Investment?

Third quarter 2023 earnings released: EPS: kr0.15 (vs kr0.11 in 3Q 2022)

We Think Arcoma (STO:ARCOMA) Is Taking Some Risk With Its Debt

Second quarter 2023 earnings released: EPS: kr0.031 (vs kr0.11 in 2Q 2022)

Is Arcoma (STO:ARCOMA) Using Too Much Debt?

First quarter 2023 earnings released: kr0.18 loss per share (vs kr0.093 loss in 1Q 2022)

Is Arcoma AB (STO:ARCOMA) Potentially Undervalued?

Full year 2022 earnings released: EPS: kr0.14 (vs kr0.58 loss in FY 2021)

Does Arcoma (STO:ARCOMA) Have A Healthy Balance Sheet?

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: kr0.11 (vs kr0.24 loss in 3Q 2021)

Second quarter 2022 earnings released: EPS: kr0.11 (vs kr0.079 in 2Q 2021)

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Is Arcoma (STO:ARCOMA) Using Too Much Debt?

Price target decreased to kr16.50

No independent directors

Director recently bought kr119k worth of stock

Full year 2021 earnings: EPS and revenues miss analyst expectations

Price target decreased to kr21.00

Third quarter 2021 earnings released: kr0.24 loss per share (vs kr0.082 profit in 3Q 2020)

These 4 Measures Indicate That Arcoma (STO:ARCOMA) Is Using Debt Extensively

Second quarter 2021 earnings released: EPS kr0.079 (vs kr0.18 in 2Q 2020)

First quarter 2021 earnings released: EPS kr0.15 (vs kr0.31 in 1Q 2020)

Is Arcoma (STO:ARCOMA) A Risky Investment?

Revenue and earnings miss expectations

Full year 2020 earnings released: EPS kr0.12 (vs kr0.52 in FY 2019)

Arcoma AB, Annual General Meeting, May 25, 2021

Is Arcoma AB (STO:ARCOMA) Potentially Undervalued?

Have Insiders Sold Arcoma AB (STO:ARCOMA) Shares Recently?

Insider recently sold kr390k worth of stock

Arcoma AB's (STO:ARCOMA) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Investor sentiment improved over the past week

New 90-day high: kr21.90

These 4 Measures Indicate That Arcoma (STO:ARCOMA) Is Using Debt Reasonably Well

Arcoma AB Launches Omnera 500A

Estimating The Fair Value Of Arcoma AB (STO:ARCOMA)

Third quarter 2020 earnings released: EPS kr0.082

Analysts update estimates

Price target lowered to kr25.00

New 90-day low: kr17.00

New 90-day low: kr17.50

Analysts increase EPS estimates to kr0.60

Earnings released

New 90-day low - kr17.70

AMMINISTRATORE DELEGATO

Mandato

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media